查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2016280

RNA干扰技术市场：2026-2032年全球市场预测（依分子类型、给药途径、递送方式、应用及最终用户划分）

RNA Interference Technology Market by Molecule Type, Route Of Administration, Delivery Method, Application, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计RNA干扰技术市场在 2025 年的价值为 35.5 亿美元，在 2026 年成长至 38.7 亿美元，到 2032 年达到 65.1 亿美元，复合年增长率为 9.05%。

主要市场统计数据
基准年 2025 35.5亿美元
预计年份：2026年 38.7亿美元
预测年份 2032 65.1亿美元
复合年增长率 (%) 9.05%

建构RNA干扰技术创新和商业化的策略框架，同时考虑到治疗方法开发和交付方面的挑战以及监管趋势。

RNA干扰（RNAi）已从实验室研究发展成为临床验证有效的治疗方法，对治疗药物开发和生物医学研究产生了深远的影响。过去十年，化学、递送系统和监管环境的进步，使得早期概念验证转化为已通过核准的药物，并拓展了涵盖多种适应症的候选药物研发管线。因此，决策者必须认识到RNAi独特的技术限制和机会，同时将其置于更广泛的创新框架中，该框架还包括互补的基因编辑和寡核苷酸疗法。

从递送平台到临床疗效验证，甚至跨模式整合，快速的技术和监管变革正在重新定义RNA干扰疗法。

在技​​术创新、监管先例和生态系统融合的共同推动下， RNA干扰领域正经历着一场变革性的转变。结合化学和标靶递送机制的突破显着提高了治疗指数和组织特异性，使以往难以应用的适应症得以实现。同时，平台技术的成熟推动了模组化开发模式的形成，使得递送载体等单一要素的最佳化能够在多个专案中重复使用，从而提高研发效率并降低专案风险。

本报告预测了美国在 2025 年实施的关税政策对全球 RNAi 供应链、采购和研究营运的累积影响。

美国2025年实施的累积关税措施凸显了全球生命科学供应链的战略脆弱性，为RNAi研发人员和供应商带来了新的成本和营运压力。由于关税导致进口试剂、特殊脂质和某些设备组件的到货成本增加，促使各方重新评估筹资策略和多源采购计划。这迫使各机构加快替代供应商的认证，优先考虑与国内製造伙伴关係，并重新评估库存管理实践，以确保专案进度。

RNAi 生态系统按分子类别、递送方法、给药途径、应用领域和最终用户角色进行细分，以明确策略重点。

对RNAi生态系进行有意义的细分，有助于明确科研努力与商业性机会的契合点。基于分子类型，市场研究已对微型RNA（miRNA）、短髮夹RNA（shRNA）和小干扰RNA（siRNA）进行了考察，并进一步将短髮夹RNA细分为非病毒载体shRNA和病毒载体shRNA，将小干扰RNA细分为偶联siRNA和非偶联siRNA。这种分子层次的分类揭示了不同的技术和调控途径。 miRNA方法通常针对调控特定通路，而shRNA构建体通常能够实现持续的基因敲低，其持久性取决于载体的选择。另一方面，siRNA计画则倾向于优先考虑化学稳定性以及与标靶的结合，以实现精准递送。

影响美洲、欧洲、中东和非洲以及亚太地区 RNAi 开发和商业化的区域趋势及其明显的营运影响。

区域趋势显着影响RNAi计画从发现到临床应用的进程。在美洲，对生物技术企业的大力投资、先进的临床试验基础设施以及对监管法规的熟悉程度，共同推动了平台创新快速应用于人体标靶研究。该地区还聚集了大量的合约开发商和专业供应商，使其成为后期工艺放大和商业化生产伙伴关係的理想之地。

透过竞争与合作并存的企业行为，RNAi 创新受到策略联盟、与 CDMO 的合作以及智慧财产权策略的影响。

RNAi领域的企业行为呈现出平台专业化、策略伙伴关係以及与合约研发生产机构（CDMO）加强协作的混合特征。技术主导公司专注于创新化学和递送技术，以便将其授权应用于多个专案；而多元化的生物製药公司则致力于针对高优先适应症进行内部研发，并在能够利用互补专长的领域中进行选择性合作，从而加速研发进程。同时，契约製造和服务供应商也不断提升自身能力，以应对寡核苷酸疗法的复杂性和监管要求，从而建构一个更模组化的生态系统。

产业领导者可透过投资递送技术、监管合规和供应链韧性来加速RNAi专案的成功，并可采取以下策略行动

产业领导者应制定切实可行的优先事项，将RNAi的潜力转化为可持续的临床和商业性成果。首先，他们应认识到早期递送方法的选择对安全性、有效性和可扩展性有显着影响，并应投资于与目标组织和临床目标相符的递送平台的能力。其次，他们应制定供应链弹性计划，包括选择经认证的替代供应商、区域生产方案和库存策略，以降低关税和地缘政治动盪的影响。第三，他们应儘早与监管机构进行频繁对话，并利用预提交会议和适应性试验设计，使安全性监测和终点选择与支付方的预期保持一致。

透过高度透明和严谨的调查方法检验对 RNAi 的策略见解，该方法结合了与专家的对话、第二手资料的整合和检验。

本研究采用严谨的混合方法，结合了专家访谈的初步质性研究和对公开科学及监管资料的结构化二次整合。初步研究包括对临床医生、药物科学家、监管顾问和生产专家的访谈，以了解实际限制和短期营运的考量。透过这些对话，我们提出了关于给药途径权衡、特定途径的安全考量以及区域推广障碍的假设。

关于RNAi研发中策略挑战的结论：科学、实施和政策的整合将影响临床疗效

总之， RNA干扰正处于一个策略转折点，持续的科学进步、监管政策的明确性以及商业性利益在此交汇，拓展了其治疗潜力。递送化学和平台优化的进步正在开拓需要精准组织标靶化的潜在适应症，而监管先例也消除了专案开发中一些过去的不确定性。然而，营运和策略的复杂性也在增加。供应链趋势、地缘政治因素以及证明实际价值的需求，都要求药物发现、开发和商业化等各环节进行整合规划。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：以分子类型分類的RNA干扰技术市场

  • 微型RNA（miRNA）
  • 短髮夹RNA（shRNA）
    • 非病毒载体shRNA
    • 病毒传播的shRNA
  • 小干扰RNA（siRNA）
    • 偶联siRNA
    • 未结合的siRNA

第九章： RNA干扰技术市场：依给药途径划分

  • 肌肉内注射
  • 鞘内（IT）给药
  • 静脉注射

第十章： RNA干扰技术市场：依递送方式划分

  • 直接递送裸露的RNAi
  • 以外泌体为基础的RNAi疗法
  • 利用奈米颗粒进行递送
  • 利用病毒载体进行递送

第十一章RNA干扰技术市场：依应用领域划分

  • 药物发现
    • 先导药物最适化
    • 目标识别
  • 研究与开发
    • 基因功能研究
    • 讯号传导通路分析
  • 治疗药物

第十二章RNA干扰技术市场：依最终用户划分

  • 合约研究机构
  • 医院和诊所
  • 製药和生物技术公司

第十三章RNA干扰技术市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章RNA干扰技术市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章RNA干扰技术市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国RNA干扰技术市场

第十七章：中国RNA干扰技术市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Alnylam Pharmaceuticals, Inc.
  • AMSBIO
  • Arbutus Biopharma Corporation
  • Arcturus Therapeutics Holdings Inc.
  • Arrowhead Pharmaceuticals, Inc.
  • Atalanta Therapeutics
  • Bioneer Corporation
  • Dicerna Pharmaceuticals, Inc.
  • Gradalis, Inc.
  • Horizon Therapeutics plc
  • Ionis Pharmaceuticals, Inc.
  • Merck KGaA
  • Novartis AG
  • Nutcracker Therapeutics, Inc.
  • Phio Pharmaceuticals Corp.
  • ProQR Therapeutics NV
  • Sanofi SA
  • Silence Therapeutics PLC
  • Sirnaomics, Inc.
  • Thermo Fisher Scientific Inc.
  • Vir Biotechnology, Inc.
Product Code: MRR-0375F3EAA810

The RNA Interference Technology Market was valued at USD 3.55 billion in 2025 and is projected to grow to USD 3.87 billion in 2026, with a CAGR of 9.05%, reaching USD 6.51 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.55 billion
Estimated Year [2026] USD 3.87 billion
Forecast Year [2032] USD 6.51 billion
CAGR (%) 9.05%

Setting the strategic context for RNA interference innovation and commercialization across therapeutic development, delivery challenges, and regulatory momentum

RNA interference (RNAi) has matured from a laboratory phenomenon into a clinically validated modality with durable implications for therapeutic development and biomedical research. Over the past decade, advances in chemistry, delivery systems, and regulatory clarity have converted early proofs of concept into approved drugs and a growing pipeline of candidates across multiple indications. As a result, decision-makers must situate RNAi within a broader innovation landscape that includes complementary gene editing and oligonucleotide approaches while recognizing unique technical constraints and opportunity windows.

This executive-level introduction frames RNAi as both a scientific platform and a commercial proposition. It highlights how improvements in stability, targeting, and manufacturing have reduced historical barriers while the ongoing evolution of delivery technologies-ranging from conjugates to nanoparticles to viral vectors-creates differentiated pathways for clinical translation. Finally, this section underscores the importance of integrating regulatory strategy, payer considerations, and downstream manufacturing readiness early in program design in order to de-risk development and accelerate time to meaningful patient impact.

Rapid technological and regulatory shifts redefining RNA interference therapeutics from delivery platforms to clinical validation and cross-modal integration

The landscape for RNA interference is undergoing transformative shifts driven by technical innovation, regulatory precedent, and ecosystem convergence. Breakthroughs in conjugation chemistry and targeted delivery mechanisms have materially improved therapeutic index and tissue specificity, enabling indications that were previously out of reach. Concurrently, the maturation of platform know-how is facilitating modular development approaches where optimization of one element-such as a delivery vehicle-can be reused across multiple programs, thereby increasing R&D efficiency and lowering program risk.

Regulatory agencies have also moved from conceptual guidance to more concrete review pathways, reducing uncertainty and enabling clearer development milestones. At the same time, cross-modal integration with complementary technologies such as gene editing and mRNA therapeutics is creating hybrid strategies that combine durable knockdown with editing or transient expression, expanding the scope of treatable diseases. Market dynamics reflect increased collaboration between platform developers, contract manufacturers, and clinical partners, which accelerates translation but also requires more sophisticated alliance management and IP strategies. Taken together, these shifts are reorienting investment and operational priorities toward scalable delivery, regulatory alignment, and strategic partnerships.

Anticipating the cumulative impact of United States tariff policies enacted in 2025 on global RNAi supply chains, sourcing, and research operations

The introduction of cumulative tariff measures by the United States in 2025 has emphasized the strategic fragility of global life sciences supply chains and highlighted new cost and operational pressures for RNAi developers and suppliers. Tariff-related increases in the landed cost of imported reagents, specialized lipids, and certain device components have triggered a reassessment of sourcing strategies and multi-sourcing plans. This has encouraged organizations to accelerate qualification of alternative suppliers, prioritize domestic manufacturing partnerships, and re-evaluate inventory management practices to preserve program timelines.

Consequently, companies are recalibrating their outsourcing models to reduce exposure to tariff volatility, increasing interest in regional contract manufacturing capacity, and reexamining the total cost of ownership for critical raw materials. In parallel, procurement and legal teams are working more closely with R&D to identify tariff-sensitive inputs early in development so that formulation design and process choices can mitigate exposure. From a strategic perspective, the tariffs have underscored the value of supply chain transparency, pre-competitive consortia for critical component production, and contingency planning that preserves clinical momentum while managing incremental cost pressures.

Segmenting the RNAi ecosystem by molecule class, delivery approach, administration route, application focus, and end-user roles to reveal strategic priorities

Meaningful segmentation of the RNAi ecosystem clarifies where scientific effort and commercial opportunity align. Based on Molecule Type, market studies consider MicroRNA (miRNA), Short Hairpin RNA (shRNA), and Small Interfering RNA (siRNA), with Short Hairpin RNA further examined across Non-Viral Delivery shRNA and Viral Delivery shRNA and Small Interfering RNA further analyzed as Conjugated siRNA and Non-Conjugated siRNA. This molecular stratification reveals distinct technical and regulatory pathways: miRNA approaches frequently target pathway modulation, shRNA constructs often enable durable knockdown with vector choices dictating persistence, and siRNA programs tend to emphasize chemical stabilization and targeted conjugation for precision delivery.

Based on Route Of Administration, the ecosystem is studied across Intramuscular (IM) Injection, Intrathecal (IT) Administration, and Intravenous (IV) Injection, each of which imposes different formulation, safety monitoring, and clinical trial design requirements. Based on Delivery Method, the field is appraised across Direct Naked RNAi Delivery, Exosome-Based RNAi Therapy, Nanoparticle-Based Delivery, and Viral Vector-Based Delivery, highlighting how payload, target tissue, and immunogenicity considerations drive modality selection. Based on Application, the landscape spans Drug Discovery, Research & Development, and Therapeutics, with Drug Discovery further broken down into Lead Optimization and Target Identification and Research & Development further divided into Gene Function Studies and Pathway Analysis. Finally, based on End-User, stakeholders include Contract Research Organizations, Hospitals & Clinics, and Pharmaceutical & Biotechnology Companies, each engaging with RNAi capabilities at different points in the value chain. Synthesizing these segmentation dimensions enables program teams to prioritize technical investments, align clinical strategy with administration routes, and select partners whose capabilities match the intended product profile.

Regional dynamics shaping RNAi development and commercialization across the Americas, Europe Middle East & Africa, and Asia-Pacific with distinct operational implications

Regional dynamics significantly influence how RNAi programs progress from discovery into clinical application. In the Americas, a combination of strong biotechnology venture investment, advanced clinical trial infrastructure, and regulatory familiarity has supported rapid translation of platform innovations into human studies. This geography also hosts a dense concentration of contract developers and specialized suppliers, making it an attractive location for late-stage process scale-up and commercial manufacturing partnerships.

In Europe, Middle East & Africa, regulatory harmonization across major markets and robust academic hubs drive translational science, while national centers of excellence contribute specialized capabilities in formulation and vector engineering. Market access pathways and payer negotiation dynamics in Europe require earlier demonstration of real-world outcomes and companion diagnostics in certain therapeutic areas. The Asia-Pacific region combines large patient populations for clinical enrollment, rapidly expanding biomanufacturing capacity, and active government initiatives to support biotechnology infrastructure. Taken together, these regional distinctions shape strategic choices about where to site clinical trials, manufacture drug product, and cultivate long-term partnerships based on regulatory environment, cost base, and talent availability.

Competitive and collaborative company behaviors shaping RNAi innovation through strategic partnerships, CDMO engagement, and intellectual property strategies

Company behavior in the RNAi domain is characterized by a mix of platform specialization, strategic partnerships, and increasing engagement with contract development and manufacturing organizations. Technology-focused firms concentrate on chemistry and delivery innovations that can be licensed across multiple programs, while diversified biopharma firms pursue in-house development for high-priority indications and selectively partner where complementary expertise accelerates timelines. At the same time, contract manufacturers and service providers are expanding capabilities to address formulation complexity and regulatory expectations for oligonucleotide therapies, creating a more modular ecosystem.

Competitive differentiation increasingly rests on the depth of delivery know-how, the strength and clarity of intellectual property portfolios, and the ability to execute late-stage manufacturing reliably. Partnerships and licensing deals remain common mechanisms to combine discovery-stage innovation with commercial-scale capabilities. Additionally, vertical integration is emerging as a strategic option for organizations seeking to control critical supply chain nodes, although this approach requires significant capital and operational sophistication. For emerging companies, judicious collaboration with experienced clinical development and manufacturing partners reduces execution risk and accelerates the path from concept to clinic.

Strategic actions for industry leaders to accelerate RNAi program success through delivery investment, regulatory alignment, and supply chain resilience

Industry leaders should adopt a set of actionable priorities to translate RNAi potential into durable clinical and commercial outcomes. First, invest in delivery platform capabilities that match target tissues and clinical objectives, recognizing that delivery choices made during early development materially affect safety, efficacy, and scalability. Second, develop supply chain resilience plans that include qualified alternate suppliers, regional manufacturing options, and inventory strategies to mitigate tariff and geopolitical disruption. Third, pursue regulatory engagement early and often, using pre-submission meetings and adaptive trial designs to align safety monitoring and endpoint selection with payer expectations.

Moreover, leaders should pursue strategic partnerships with contract development and manufacturing organizations to de-risk scale-up while retaining optionality for manufacturing ownership in the future. They should also prioritize data interoperability and real-world evidence collection to support both regulatory submissions and payer value demonstration. Finally, invest in talent and governance structures that enable rapid learning across platforms-creating cross-functional teams that bridge discovery chemistry, translational pharmacology, clinical development, and commercial strategy to accelerate decision-making and program progress.

Transparent and rigorous research methodology combining expert engagement, secondary synthesis, and triangulation to validate RNAi strategic insights

This research employs a rigorous mixed-methods approach combining primary qualitative engagement with subject-matter experts and structured secondary synthesis of public scientific and regulatory sources. Primary research included interviews with clinicians, formulation scientists, regulatory advisors, and manufacturing specialists to capture practical constraints and near-term operational considerations. These conversations informed hypothesis generation around delivery trade-offs, route-specific safety considerations, and regional implementation barriers.

Secondary research synthesized peer-reviewed literature, clinical trial registries, regulatory guidance documents, and company disclosures to contextualize primary insights and validate technical assertions. Data triangulation ensured that conclusions reflected convergent evidence rather than single-source assumptions, and quality checks included cross-validation of technical details with independently published protocols and regulatory filings. The methodology also accounted for limitations, noting areas where data remain emergent-such as long-term real-world safety for new delivery modalities-and recommending targeted follow-up studies to address these gaps.

Concluding perspectives on the strategic imperatives for RNAi development as science, delivery, and policy converge to shape clinical impact

In summary, RNA interference stands at a strategic inflection point where sustained scientific progress, evolving regulatory clarity, and commercial interest converge to expand therapeutic potential. Progress in delivery chemistry and platform optimization is unlocking indications that require precise tissue targeting, while regulatory precedents reduce some historical uncertainty for program development. Nevertheless, operational and strategic complexity has increased: supply chain dynamics, geopolitical considerations, and the imperative to demonstrate real-world value demand integrated planning across discovery, development, and commercialization functions.

Organizations that succeed will be those that harmonize scientific ambition with pragmatic operational execution-investing early in delivery solutions, diversifying sourcing and manufacturing strategies, engaging regulators proactively, and forming targeted partnerships to access missing capabilities. By aligning technical design choices with clinical and commercial constraints, program teams can accelerate translation while preserving flexibility to adapt to emerging data and market signals. The path forward requires disciplined program design, robust external collaboration, and sustained investment in the capabilities that convert molecular promise into patient benefit.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. RNA Interference Technology Market, by Molecule Type

  • 8.1. MicroRNA (miRNA)
  • 8.2. Short Hairpin RNA (shRNA)
    • 8.2.1. Non-Viral Delivery shRNA
    • 8.2.2. Viral Delivery shRNA
  • 8.3. Small Interfering RNA (siRNA)
    • 8.3.1. Conjugated siRNA
    • 8.3.2. Non-Conjugated siRNA

9. RNA Interference Technology Market, by Route Of Administration

  • 9.1. Intramuscular (IM) Injection
  • 9.2. Intrathecal (IT) Administration
  • 9.3. Intravenous (IV) Injection

10. RNA Interference Technology Market, by Delivery Method

  • 10.1. Direct Naked RNAi Delivery
  • 10.2. Exosome-Based RNAi Therapy
  • 10.3. Nanoparticle-Based Delivery
  • 10.4. Viral Vector-Based Delivery

11. RNA Interference Technology Market, by Application

  • 11.1. Drug Discovery
    • 11.1.1. Lead Optimization
    • 11.1.2. Target Identification
  • 11.2. Research & Development
    • 11.2.1. Gene Function Studies
    • 11.2.2. Pathway Analysis
  • 11.3. Therapeutics

12. RNA Interference Technology Market, by End-User

  • 12.1. Contract Research Organizations
  • 12.2. Hospitals & Clinics
  • 12.3. Pharmaceutical & Biotechnology Companies

13. RNA Interference Technology Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. RNA Interference Technology Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. RNA Interference Technology Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States RNA Interference Technology Market

17. China RNA Interference Technology Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Alnylam Pharmaceuticals, Inc.
  • 18.6. AMSBIO
  • 18.7. Arbutus Biopharma Corporation
  • 18.8. Arcturus Therapeutics Holdings Inc.
  • 18.9. Arrowhead Pharmaceuticals, Inc.
  • 18.10. Atalanta Therapeutics
  • 18.11. Bioneer Corporation
  • 18.12. Dicerna Pharmaceuticals, Inc.
  • 18.13. Gradalis, Inc.
  • 18.14. Horizon Therapeutics plc
  • 18.15. Ionis Pharmaceuticals, Inc.
  • 18.16. Merck KGaA
  • 18.17. Novartis AG
  • 18.18. Nutcracker Therapeutics, Inc.
  • 18.19. Phio Pharmaceuticals Corp.
  • 18.20. ProQR Therapeutics N.V.
  • 18.21. Sanofi S.A.
  • 18.22. Silence Therapeutics PLC
  • 18.23. Sirnaomics, Inc.
  • 18.24. Thermo Fisher Scientific Inc.
  • 18.25. Vir Biotechnology, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MICRORNA (MIRNA), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MICRORNA (MIRNA), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MICRORNA (MIRNA), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY NON-VIRAL DELIVERY SHRNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY NON-VIRAL DELIVERY SHRNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY NON-VIRAL DELIVERY SHRNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY VIRAL DELIVERY SHRNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY VIRAL DELIVERY SHRNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY VIRAL DELIVERY SHRNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SMALL INTERFERING RNA (SIRNA), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SMALL INTERFERING RNA (SIRNA), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SMALL INTERFERING RNA (SIRNA), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SMALL INTERFERING RNA (SIRNA), 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY CONJUGATED SIRNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY CONJUGATED SIRNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY CONJUGATED SIRNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY NON-CONJUGATED SIRNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY NON-CONJUGATED SIRNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY NON-CONJUGATED SIRNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY INTRAMUSCULAR (IM) INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY INTRAMUSCULAR (IM) INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY INTRAMUSCULAR (IM) INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY INTRATHECAL (IT) ADMINISTRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY INTRATHECAL (IT) ADMINISTRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY INTRATHECAL (IT) ADMINISTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY INTRAVENOUS (IV) INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY INTRAVENOUS (IV) INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY INTRAVENOUS (IV) INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DIRECT NAKED RNAI DELIVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DIRECT NAKED RNAI DELIVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DIRECT NAKED RNAI DELIVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY EXOSOME-BASED RNAI THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY EXOSOME-BASED RNAI THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY EXOSOME-BASED RNAI THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY NANOPARTICLE-BASED DELIVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY NANOPARTICLE-BASED DELIVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY NANOPARTICLE-BASED DELIVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY VIRAL VECTOR-BASED DELIVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY VIRAL VECTOR-BASED DELIVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY VIRAL VECTOR-BASED DELIVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY LEAD OPTIMIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY LEAD OPTIMIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY LEAD OPTIMIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TARGET IDENTIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TARGET IDENTIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TARGET IDENTIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY GENE FUNCTION STUDIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY GENE FUNCTION STUDIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY GENE FUNCTION STUDIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY PATHWAY ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY PATHWAY ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY PATHWAY ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SMALL INTERFERING RNA (SIRNA), 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SMALL INTERFERING RNA (SIRNA), 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SMALL INTERFERING RNA (SIRNA), 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SMALL INTERFERING RNA (SIRNA), 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SMALL INTERFERING RNA (SIRNA), 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SMALL INTERFERING RNA (SIRNA), 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SMALL INTERFERING RNA (SIRNA), 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SMALL INTERFERING RNA (SIRNA), 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SMALL INTERFERING RNA (SIRNA), 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 175. GCC RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 176. GCC RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. GCC RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), 2018-2032 (USD MILLION)
  • TABLE 178. GCC RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SMALL INTERFERING RNA (SIRNA), 2018-2032 (USD MILLION)
  • TABLE 179. GCC RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 180. GCC RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 181. GCC RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 182. GCC RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 183. GCC RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 184. GCC RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SMALL INTERFERING RNA (SIRNA), 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), 2018-2032 (USD MILLION)
  • TABLE 198. BRICS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SMALL INTERFERING RNA (SIRNA), 2018-2032 (USD MILLION)
  • TABLE 199. BRICS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 205. G7 RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 206. G7 RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. G7 RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), 2018-2032 (USD MILLION)
  • TABLE 208. G7 RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SMALL INTERFERING RNA (SIRNA), 2018-2032 (USD MILLION)
  • TABLE 209. G7 RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 210. G7 RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 211. G7 RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 212. G7 RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 213. G7 RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 214. G7 RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 215. NATO RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 216. NATO RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. NATO RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), 2018-2032 (USD MILLION)
  • TABLE 218. NATO RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SMALL INTERFERING RNA (SIRNA), 2018-2032 (USD MILLION)
  • TABLE 219. NATO RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 220. NATO RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 221. NATO RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 222. NATO RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 223. NATO RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 224. NATO RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 225. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 226. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 227. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SMALL INTERFERING RNA (SIRNA), 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 236. CHINA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 237. CHINA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. CHINA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), 2018-2032 (USD MILLION)
  • TABLE 239. CHINA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SMALL INTERFERING RNA (SIRNA), 2018-2032 (USD MILLION)
  • TABLE 240. CHINA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 241. CHINA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 243. CHINA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 244. CHINA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 245. CHINA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)